The FDA's data on mifepristone can't be trusted — here's why

For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.

Summary aggregated from The Hill's public RSS feed. The full reporting belongs to The Hill — please read it on their site.